Health Care • Biotechnology: Pharmaceutical Preparations
$56.69 ▲ +1.37
(+2.48%)
MKT CAP: $556.7M • VOL: 67.6K
52W L $47 52W H $124
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$48
MEDIAN
$63
MEAN
$65
HIGH
$77
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE DRUG TAPE
DRUG // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $68.59 | $65.19 | 2025-02-14 | $51.59 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $71.43 | $66.89 | 2025-02-06 | $53.29 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $64.63 | $62.36 | 2025-01-29 | $54.42 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $57.82 | — | 2025-01-17 | $55.56 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $49.89 | $53.86 | 2025-01-09 | $50.45 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $67.46 | $58.96 | 2024-12-18 | $49.32 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $54.99 | $57.26 | 2024-12-04 | $52.72 | -4.3% | 48% | C |